RecruitingNCT06889974

Timing of Renal Replacement Therapy Initiation in Tumor Lysis Syndrome


Sponsor

University Hospital, Bordeaux

Enrollment

800 participants

Start Date

Jul 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The TENDERS study aims to evaluate the impact of the timing of renal replacement therapy (RRT) initiation on outcomes in patients with tumor lysis syndrome (TLS) and associated acute kidney injury (AKI). The study will compare early versus delayed RRT initiation, examining the effect on renal function at 30 days post-treatment.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Adults aged ≥18 years.
  • Hospitalized in the ICU between January 1, 2013, and December 31, 2023.
  • Diagnosed with a hematologic malignancy or solid tumor requiring chemotherapy.
  • Diagnosed with TLS based on the presence of two or more biochemical criteria (e.g., hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia) within 3 days before or 7 days after chemotherapy initiation.

Exclusion Criteria2

  • Patient or family opposition to data collection for research purposes.
  • Incomplete medical records that preclude data extraction.

Locations(10)

CHU d'Angers

Angers, France

Hôpital Pellegrin

Bordeaux, France

Hôpital la cavale blanche

Brest, France

CHU Dupuytren 1

Limoges, France

Hôtel-Dieu

Nantes, France

CHR d'Orléans

Orléans, France

CH de Pau

Pau, France

Centre Urgences-Réanimations

Rennes, France

IUCT-O Hopital Purpan

Toulouse, France

Hôpital Bretonneau

Tours, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06889974